Plain Language Summary on Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa‐ PROTECT Main Study

European Journal Of Haematology 2026 Open access

Read full text
Authors: Margareth C Ozelo, Matteo Luciani, Heidi Glosli, Kaan Kavaklı, Nasrin Samji, Gregory C. Makris, Claudia Tueckmantel, Monika Maas Enriquez, Luciana C. Oliveira, Shveta Gupta, Guillermo Arbesú, Mauro R. Davoli
+2 more Anthony K. C. Chan, Maria Elisa Mancuso
DOI: 10.1111/ejh.70078
Cited by: 0

Abstract

This is a plain language summary describing results from the Alfa-PROTECT study on safety and efficacy of damoctocog alfa pegol in previously treated children aged between 7 and 12 years with severe haemophilia A. Trial Registration: The Alfa-PROTECT trial is registered at ClinicalTrials.gov: NCT05147662.

Fields of Study & Subjects

Hemophilia Treatment and Research Platelet Disorders and Treatments Blood transfusion and management

Publication details

Journal / source
European Journal Of Haematology
Volume
116
Issue
4
Pages
471–472
Publication date
14 January 2026
Language
EN